The effects of sodium-glucose cotransporter 2 inhibitors (iSGLT2) use on cardiac arrhythmias: integrative review

Abstract

Cardiac arrhythmias represent one of the main causes of sudden death globally. Studies with sodium-glucose cotransporter 2 (iSGLT2) inhibitors - originally a class of antidiabetics - are also demonstrating cardiovascular benefits. This study aims to review articles that demonstrate the effects of using iSGLT2 on cardiac arrhythmias. Methods: 270 articles were initially located on the PubMed and Lilacs platforms after searching for keywords in English: “isglt2”, “sglt2 inhibitor”, “glucose-sodium cotransporter 2 inhibitor”, “cardiac arrhythmia” and “arrhythmia. Subsequently, a restricted filter was adopted for articles published in the last four years, going from September 2019 to September 2023 and then restricted to the type of study and, finally, titles and abstracts and articles in the complete, resulting in 11 articles selected for the integrative review. This review demonstrates that the use of sodium-glucose cotransporter 2 (iSGLT2) inhibitors demonstrates encouraging results in relation to the effects on arrhythmias, preventing and reducing arrhythmic events of atrial or ventricular nature, and may be potential new therapeutic options in certain clinical conditions that may trigger an arrhythmia or arrhythmias themselves. Keywords: iSGLT2, cardiac arrhythmias, effects.